<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299464</url>
  </required_header>
  <id_info>
    <org_study_id>BP41316</org_study_id>
    <secondary_id>2019-003524-20</secondary_id>
    <nct_id>NCT04299464</nct_id>
  </id_info>
  <brief_title>A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of
      RO7017773 in participants aged 15-45 years who have been diagnosed with ASD and who have a
      score of &gt;/=50 on the Wechsler Abreviated Scale of Intelligence (WASI-II).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 12 in the Adaptive Behavior Composite score of the Vineland Adaptive Behavior Scales, Second Edition (Vineland 11)</measure>
    <time_frame>Baseline up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Treatment due to AEs</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in Suicide Risk Using the Columbia-Suicide-Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline, Days 1, 14, 42, 84, 98, 126</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 in Behavior/Symptoms as Measured by all Domains of the Repetitive Behavior Scale-Revised (RBS-R)</measure>
    <time_frame>Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Autism Spectrum Disorder (ASD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to RO7017773 for approximately 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7017773 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO7017773 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive oral placebo for approximately 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7017773</intervention_name>
    <description>Participants will receive oral RO7017773 for approximately 12 weeks.</description>
    <arm_group_label>RO7017773 High Dose</arm_group_label>
    <arm_group_label>RO7017773 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male and female participants with Autism Spectrum Disorder according to Diagnostic and
             Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

          -  Wechsler Abbreviated Scale of Intelligence (WASI-II) &gt;= 50 at screening or within the
             last 12 months prior to screening

          -  ASD or Autism diagnosis confirmed by Autism Diagnostic Observation Schedule (ADOS-2)

          -  Body mass index within the range of 18.5 to 40 kg/m2

          -  Female Participants: is eligible if she is not pregnant, not breastfeeding, and women
             of childbearing potential (WOCBP), who agree to remain abstinent or use contraceptive
             methods that result in a failure rate of &lt; 1% per year during the treatment period and
             for at least 28 days after the last dose of study drug

          -  Language, hearing, and vision compatible with the study measurements as judged by the
             Investigator

          -  Allowed existing treatment regimens should be stable for 8 weeks prior to screening.
             Investigator expects stability of these treatments and behavioral interventions for
             the duration of the study

          -  In the Investigator's opinion, able to participate and deemed appropriate for
             participation in the study, capable of following the study SoA and able to comply with
             the study restrictions

          -  In the Investigator's opinion, participation in the study or discontinuation of
             prohibited medication will not pose undue risks

        Exclusion Criteria

        Neurologic/Psychiatric Conditions:

          -  Presence of genetically defined ASD per genetic results available prior to screening
             or known &quot;syndromic&quot; forms of ASD (e.g. fragile X syndrome, chromosome 15q11.2-q13.1
             duplication syndrome (Dup15q syndrome), Prader Willi syndrome, Rett's syndrome, or
             tuberous sclerosis)

          -  Medical history of alcohol and/or substance abuse/dependence in the last 12 months or
             positive test for drugs of abuse at screening

          -  Initiation of a major change in psychosocial intervention within 4 weeks prior to
             screening. Minor changes in ongoing treatment are not considered major changes

          -  Unstable or uncontrolled clinically significant psychiatric and/or neurological
             disorder that may interfere with the safety or efficacy endpoints

          -  Risk of suicidal behavior in the opinion of a certified clinician or as evidenced by a
             &quot;yes&quot; to questions 4 and/or 5 of Columbia-Suicide-Severity Rating Scale (C-SSRS) taken
             at screening and baseline with respect to the last 12 months, or any suicide attempt
             in the past 5 years

          -  Unstable epilepsy/seizure disorder within the past 6 months or changes in
             anticonvulsive therapy within the last 6 months

        Other Conditions:

          -  Medical history of malignancy if not considered cured or if occurred within the last 3
             years with the exception of fully excised non-melanoma skin cancers or in-situ
             carcinoma of the cervix that has been successfully treated

          -  Concomitant disease, condition or treatment which would either interfere with the
             conduct of the study or pose an unacceptable risk to the participant in the opinion of
             the Investigator Prior/Concomitant Therapy

          -  Use of prohibited medications or herbal remedies within 6 weeks or 5 half-lives (t1/2)
             prior to randomization

        Prior/Concurrent Clinical Study Experience:

          -  Donation or loss of blood over 500 mL in adults and 250 mL in adolescents within 3
             months prior to randomization

          -  Participation in an investigational drug study within 1 month or 5 times the t1/2 of
             the investigational molecule prior to randomization or participation in a study
             testing an investigational medical device within 1 month prior to randomization or if
             the device is still active Diagnostic Assessments

          -  Confirmed clinically significant abnormality in hematological, chemistry or
             coagulation laboratory parameters

          -  Positive test result at screening for hepatitis B surface antigen, hepatitis C virus
             (HCV, untreated), or human immunodeficiency virus (HIV)-1 and -2. HCV participants who
             have been successfully treated and who test negative for HCV RNA, may be considered
             eligible for entry into the study

        Other Exculsions:

          -  Uncorrected hypokalemia or hypomagnesaemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP41316 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southwest Autism Research &amp; Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University / Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519-1124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America, LLC</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APG- Advanced Psychiatric Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials, LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital; Lurie Center for Autism</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414-2959</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin, PC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OCT Research ULC</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Childrens Health; and Rehabilitation Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre</name>
      <address>
        <city>East York</city>
        <state>Ontario</state>
        <zip>M4G 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario/Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

